# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

> **NCT02760316** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** AZD9567 10 mg
- **DRUG:** AZD9567 20 mg
- **DRUG:** AZD9567 40 mg
- **DRUG:** AZD9567 80 mg
- **DRUG:** Prednisolone 20 mg
- **DRUG:** AZD9567 125 mg
- **DRUG:** AZD9567 155 mg
- **DRUG:** Prednisolone 5 mg
- **DRUG:** Prednisolone 40 mg

## Key facts

- **NCT ID:** NCT02760316
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-02
- **Primary completion:** 2017-09-11
- **Final completion:** 2017-09-11
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2017-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760316, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02760316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*